Raymond James Financial Services Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.64M | Sell |
17,268
-1,146
| -6% | -$109K | ﹤0.01% | 1852 |
|
|
2024
Q2 | $1.68M | Buy |
18,414
+628
| +4% | +$57.5K | ﹤0.01% | 1772 |
|
|
2024
Q1 | $1.61M | Sell |
17,786
-362
| -2% | -$32.8K | ﹤0.01% | 1756 |
|
|
2023
Q4 | $1.48M | Buy |
18,148
+14,921
| +462% | +$1.21M | ﹤0.01% | 1737 |
|
|
2023
Q3 | $258K | Sell |
3,227
-83
| -3% | -$6.63K | ﹤0.01% | 2762 |
|
|
2023
Q2 | $261K | Buy |
3,310
+548
| +20% | +$43.2K | ﹤0.01% | 2753 |
|
|
2023
Q1 | $214K | Sell |
2,762
-19,602
| -88% | -$1.52M | ﹤0.01% | 2855 |
|
|
2022
Q4 | $1.74M | Buy |
22,364
+19,106
| +586% | +$1.49M | ﹤0.01% | 1514 |
|
|
2022
Q3 | $219K | Sell |
3,258
-68
| -2% | -$4.57K | ﹤0.01% | 2789 |
|
|
2022
Q2 | $256K | Sell |
3,326
-145
| -4% | -$11.2K | ﹤0.01% | 2695 |
|
|
2022
Q1 | $277K | Buy |
3,471
+167
| +5% | +$13.3K | ﹤0.01% | 2760 |
|
|
2021
Q4 | $254K | Buy |
3,304
+23
| +0.7% | +$1.77K | ﹤0.01% | 2811 |
|
|
2021
Q3 | $239K | Buy |
3,281
+464
| +16% | +$33.8K | ﹤0.01% | 2847 |
|
|
2021
Q2 | $206K | Buy |
+2,817
| New | +$206K | ﹤0.01% | 2993 |
|
|
2018
Q2 | – | Sell |
-4,220
| Closed | -$240K | – | 2798 |
|
|
2018
Q1 | $240K | Sell |
4,220
-1,672
| -28% | -$95.1K | ﹤0.01% | 2148 |
|
|
2017
Q4 | $350K | Buy |
5,892
+71
| +1% | +$4.22K | ﹤0.01% | 1928 |
|
|
2017
Q3 | $336K | Sell |
5,821
-42,791
| -88% | -$2.47M | ﹤0.01% | 1961 |
|
|
2017
Q2 | $2.87M | Buy |
48,612
+42,944
| +758% | +$2.54M | 0.02% | 723 |
|
|
2017
Q1 | $313K | Buy |
+5,668
| New | +$313K | ﹤0.01% | 1872 |
|
|
2016
Q3 | – | Sell |
-35,335
| Closed | -$2.07M | – | 2322 |
|
|
2016
Q2 | $2.07M | Buy |
+35,335
| New | +$2.07M | 0.02% | 714 |
|